Skip to main content
Premium Trial:

Request an Annual Quote

Sean Freeman

Molecular Assemblies has appointed Sean Freeman to its board of directors. Freeman currently serves as head of strategy and corporate development at NuVasive. He previously served as senior VP of business development for Cole-Parmer Instrument, and as head of corporate ventures and M&A at Life Technologies, which was later acquired by Thermo Fisher Scientific. He has also worked as an investment banker in Merrill Lynch's mergers & acquisitions group.

The Scan

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.

Estonian Biobank Team Digs into Results Return Strategies, Experiences

Researchers in the European Journal of Human Genetics outline a procedure developed for individual return of results for the population biobank, along with participant experiences conveyed in survey data.

Rare Recessive Disease Insights Found in Individual Genomes

Researchers predict in Genome Medicine cross-population deletions and autosomal recessive disease impacts by analyzing recurrent nonallelic homologous recombination-related deletions.

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.